Followers | 155 |
Posts | 12584 |
Boards Moderated | 0 |
Alias Born | 12/29/2013 |
Monday, May 06, 2019 8:57:21 AM
7:45 AM ET 5/6/19 | Dow Jones
PHOENIX and ROME, May 6, 2019 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTCQB-CELZ) announced today coverage of its patented CaverStem(R) technology for treatment of erectile dysfunction using the patient's own non-manipulated and non-expanded stem cells in multiple Italian publications.
"We are pleased that our CaverStem(R) procedure has gained such international exposure in the few months since Prof. Gabriele Antonini MD, PhD has begun treating patients in Italy," said Timothy Warbington, CEO of Creative Medical Technology Holdings, Inc.
The publications include: Adnkronos, Momento Italia, DottNet and Secolo de Italia. Excerpts of the interview with Dr. Antonini, translated from Italian to English are as follows:
"A natural, non-invasive and permanent treatment to regenerate blood vessels and smooth muscles within the sexual organ of patients with erectile dysfunction. A real 'bombshell' to revive their sex life. It's called CaverStem(R) and is a patented medical protocol in the United States, also available in Italy," emphasizes the Adnkronos Salute Gabriele Antonini, urologist-andrologist from Rome.
"In the field of biomedical research, regenerative medicine has successfully established itself in the last decade through the development of new strategies and alternative treatments to conventional therapies, using growth factors and other intercellular signals capable of stimulating the natural process of healing of the human body," remarks Dr. Antonini.
So, how does 'bombing' with stem cells work? "We use hematopoietic, mesenchymal and endothelial progenitor cells present in the patient's bone marrow," explains Dr. Antonini. "The administration of stem cells directly into the penis can reverse the pathophysiological changes that lead to erectile dysfunction, in addition to treating the symptoms effectively. In about 15 minutes, the urologist specialist proceeds with local anesthesia to extract a small amount of autologous material from the iliac crest from the patient and obtains a concentrated cellular product that is injected into the corpus cavernosum of the patient's penis."
"The CaverStem(R) procedure, scientifically already validated in the USA, allows for a safe, fast and free of collateral effects in an outpatient procedure," highlights Dr. Antonini. "Only three months after implantation, an increase in duration and frequency of erection was detected, in addition to maintaining it until orgasm was reached."
"The side effects are practically absent, and no post-procedure complication has occurred," explains Dr. Antonini. "CaverStem(R) shows a truly rosy future for the non-invasive and non-surgical treatment of erectile dysfunction."
"The patient progress in Italy is indicative of reports by physicians in the United States. We are continuing to bring on board other domestic and international physicians and are highly optimistic with the future of CaverStem(R) in the United States and Internationally," said Timothy Warbington.
CaverStem(R) is a registered trademark in the United States and a pending trademark in The European Union.
For more information on our erectile dysfunction technology please go to www.Caverstem.com.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTCQB under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com.
Forward Looking Statements
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.
Publications cited:
https://www.adnkronos.com/salute/medicina/2019/05/04/dagli-usa-italia-staminali-bombita-contro-disfunzione-erettile_JgeCu0fOCt6ChtwQ4XDEGN.html?refresh_ce
https://www.dottnet.it/articolo/27651/contro-la-disfunzione-erettile-trattamento-con-staminali/
https://www.secoloditalia.it/2019/05/sanita-ce-il-si-del-ministero-in-italia-la-bombita-per-rilanciare-la-vita-sessuale/
https://www.momentoitalia.it/sesso-dagli-usa-in-italia-le-staminali-bombita-contro-disfunzione-erettile/61549/
View original content:http://www.prnewswire.com/news-releases/caverstem-stem-cell-treatment-of-erectile-dysfunction-receives-additional-international-exposure-300844049.html
SOURCE Creative Medical Technology Holdings, Inc.
/CONTACT: Creative Medical Technology Holdings, Inc., ceo@creativemedicalhealth.com, Tel: 480-789-9939
/Web site: http://creativemedicaltechnology.com
> Dow Jones Newswires
May 06, 2019 07:45 ET (11:45 GMT)
Recent CELZ News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 08:10:25 PM
- Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program • GlobeNewswire Inc. • 07/24/2024 01:00:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • GlobeNewswire Inc. • 07/10/2024 12:30:00 PM
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM